Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

August 31, 2028

Conditions
Lung Cancer (NSCLC)
Interventions
DRUG

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

Patients will receive 3-4 cycles of neoadjuvant treatment with preoperative suglizumab in combination with chemotherapy, followed by surgery. After surgery, patients will receive 1-4 cycles of platinum-containing adjuvant chemotherapy,followed by 1 year of adjuvant sugemalimab.

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai, China, Shanghai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER